What question did this study set out to answer?

To review the distinct biological mechanisms of the CTLA-4 and PD-1 pathways and assess the therapeutic implications of their inhibition in cancer treatment.

November 11, 2015American Journal of Clinical OncologyOpen Access

CTLA-4 and PD-1 Pathways

View Full Paper

Ask AI

Bookmark

To review the distinct biological mechanisms of the CTLA-4 and PD-1 pathways and assess the therapeutic implications of their inhibition in cancer treatment.
Review of pharmacological profiles and clinical indications for approved checkpoint inhibitors, including ipilimumab, nivolumab, and pembrolizumab.
Comparative mechanistic analysis of immune checkpoint regulation across lymph nodes and peripheral tissues.
CTLA-4 suppresses early T-cell proliferation primarily within lymph nodes, whereas PD-1 acts later to inhibit T-cell effector functions directly within peripheral tissues.
Therapeutic blockade of CTLA-4 and PD-1 pathways, administered as monotherapy or combination therapy, restores antitumor immune responses in advanced melanoma and refractory non-small cell lung cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Mechanistic review demonstrates distinct temporal and anatomical roles of CTLA-4 and PD-1 checkpoints in cancer, highlighting distinct clinical therapeutic profiles for immune checkpoint inhibitors.

Cite This Study

Buchbinder et al. (2015) studied this question.

synapsesocial.com/papers/69d56c3f75589c71d767cd2a https://doi.org/10.1097/coc.0000000000000239

View Full Paper

Ask AI

Bookmark

Implication

Mechanistic review demonstrates distinct temporal and anatomical roles of CTLA-4 and PD-1 checkpoints in cancer, highlighting distinct clinical therapeutic profiles for immune checkpoint inhibitors.

CTLA-4 and PD-1 Pathways

Key Points

Discussion

Implication

Cite This Study

CTLA-4 and PD-1 Pathways

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading